Fig. 4From: An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE studyMedian change from baseline in EQ-5D total and health state score. a) Median EQ-5D total score at baseline was 0.69; b) Median EQ-5D health state score at baseline was 50.0. Both scores were evaluated at administration visit 2 through administration visit 8.† EQ-5D = EuroQol 5-Dimension Questionnaire. *P < 0.001 Wilcoxon signed rank test for change versus baseline (level of significance, 5%). †The numbers of patients in administration (Admin) visits 9–13 were as follows: Admin 9, n = 111; Admin 10, n = 47; Admin 11, n = 23; Admin 12, n = 12; Admin 13, n = 6. Median changes from baseline for Admin visits 9–13 were each significant for the total score (Admin 9–11, P < 0.001; Admin 12, P = 0.006; Admin 13, P = 0.031) and the health state score (Admin 9–11, P < 0.001; Admin 12, P = 0.002; Admin 13, P = 0.031)Back to article page